Please ensure Javascript is enabled for purposes of website accessibility

Trial for a Coronavirus Vaccine to Start on Monday

By Prosper Junior Bakiny - Mar 15, 2020 at 10:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

While this is good news, let's not get too excited yet.

The COVID-19 pandemic is getting worse, both in the U.S. and worldwide. According to the World Health Organization (WHO), as of March 15, there are more than 153,000 confirmed cases of the rapidly spreading disease in the world and more than 5,700 deaths. Many states in the U.S. are now taking drastic measures to mitigate the spread of the disease, such as closing public schools and banning large gatherings. 

Fortunately, several biotech companies are racing to develop a vaccine or a treatment for the novel coronavirus. According to an unnamed government official, clinical trials for a potential vaccine for COVID-19 will start on March 16. The U.S. National Institutes of Health (NIH) is funding the trial, and the vaccine in question was developed by Moderna (MRNA 4.57%) in collaboration with the NIH. The trial will involve 45 volunteers, each of which will receive shots with different doses of the vaccine. The goal of this trial is to ensure that the vaccine doesn't cause significant adverse side effects.

Nurse holding test tube with blood for Coronavirus testing.

Image source: Getty Images.

Still a long road ahead

The fact that a trial for a potential vaccine for COVID-19 is about to start is unquestionably a step in the right direction. However, it is essential to temper our expectations. Even if this trial and potential subsequent trials don't encounter any hiccups, we're still at least a year away from having this vaccine available to the public. Of course, there's always the possibility that the vaccine fails to demonstrate its efficacy in preventing COVID-19 in later trials, assuming it makes it to that stage. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$166.85 (4.57%) $7.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
322%
 
S&P 500 Returns
113%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.